Zhu Zhu

Dr. Zhu Zhu

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2019 in Hepatology
Verified
Journal Article
Open access
PDF file
YWYun‐Long Wang
Yun‐Long Wang
JLJin‐Yu Liu
Jin‐Yu Liu
JYJin‐E Yang
Jin‐E Yang
XYXiao‐Man Yu
Xiao‐Man Yu
ZCZhan‐Li Chen
Zhan‐Li Chen
SZShi‐Mei Zhuang
Shi‐Mei Zhuang
Although thousands of long noncoding RNAs (lncRNAs) have been annotated, only a limited number of them have been functionally characterized. Here, we identified an oncogenic lncRNA, named lnc‐UCID (lncRNA up‐regulating CDK6 by interacting with DHX9). Lnc‐UCID was up‐regulated in hepatocellular carcinoma (HCC), and a higher lnc‐UCID level was correlated with shorter recurrence‐free survival of HCC patients. Both gain‐of‐function and loss‐of function studies revealed that lnc‐UCID enhanced cyclin‐dependent kinase 6 (CDK6) expression and thereby promoted G1/S transition and cell proliferation. Studies from mouse xenograft models revealed that tumors derived from lnc‐UCID‐silenced HCC cells had a much smaller size than those from control cells, and intratumoral injection of lnc‐UCID small interfering RNA suppressed xenograft growth. Mechanistically, the 850‐1030‐nt domain of lnc‐UCID interacted physically with DEAH (Asp‐Glu‐Ala‐His) box helicase 9 (DHX9), an RNA helicase. On the other hand, DHX9 post‐transcriptionally suppressed CDK6 expression by binding to the 3′‐untranslated region (3′UTR) of CDK6 mRNA. Further investigation disclosed that lnc‐UCID enhanced CDK6 expression by competitively binding to DHX9 and sequestering DHX9 from CDK6‐3′UTR. In an attempt to explore the mechanisms responsible for lnc‐UCID up‐regulation in HCC, we found that the lnc‐UCID gene was frequently amplified in HCC. Furthermore, miR‐148a, whose down‐regulation was associated with an increase of lnc‐UCID in HCC, could bind lnc‐UCID and inhibit its expression. Conclusion: Up‐regulation of lnc‐UCID, which may result from amplification of its gene locus and down‐regulation of miR‐148a, can promote HCC growth by preventing the interaction of DHX9 with CDK6 and subsequently enhancing CDK6 expression. These findings provide insights into the biological functions of lncRNAs, the regulatory network of cell cycle control, and the mechanisms of HCC development, which may be exploited for anticancer therapy.

11 July 2019 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
YLYi-Fang Lin
Yi-Fang Lin
MXMan-Huan Xiao
Man-Huan Xiao
HCHua-Xing Chen
Hua-Xing Chen
YMYu Meng
Yu Meng
NZNa Zhao
Na Zhao
SZShi-Mei Zhuang
Shi-Mei Zhuang
Micropeptides belong to a class of newly identified small molecules with <100 amino acids in length, and their functions remain largely unknown. Here, we identified a novel muscle-enriched micropeptide that was localized to mitochondria (named MPM, micropeptide in mitochondria) and upregulated during in vitro differentiation of C2C12 myoblasts and in vivo early postnatal skeletal muscle development, and muscle regeneration after cardiotoxin (CTX) damage. Downregulation of MPM was observed in the muscular tissues of tibial muscular dystrophy and Duchenne muscular dystrophy patients. Furthermore, MPM silencing inhibited the differentiation of C2C12 myoblasts into myotubes, whereas MPM overexpression stimulated it. MPM−/− mice exhibited smaller skeletal muscle fibers and worse muscle performance, such as decrease in the maximum grip force of limbs, the latency to fall off rotarod, and the exhausting swimming time. Muscle regeneration was also impaired in MPM−/− mice, as evidenced by lower expression of Pax7, MyoD, and MyoG after CTX injection and smaller regenerated myofibers, compared with wild-type mice. Mechanistical investigations based on both gain- and loss-of function studies revealed that MPM increased oxygen consumption and ATP production of mitochondria. Moreover, ectopic expression of PGC-1α, which can enhance mitochondrial respiration, attenuated the inhibitory effect of siMPM on myogenic differentiation. These results imply that MPM may promote myogenic differentiation and muscle fiber growth by enhancing mitochondrial respiratory activity, which highlights the importance of micropeptides in the elaborate regulatory network of both myogenesis and mitochondrial activity and implicates MPM as a potential target for muscular dystrophy therapy.

1 February 2022 in Molecular Therapy
Verified
Journal Article
Open access
MXMan-Huan Xiao
Man-Huan Xiao
YLYi-Fang Lin
Yi-Fang Lin
PXPeng-Peng Xie
Peng-Peng Xie
HCHua-Xing Chen
Hua-Xing Chen
JDJun-Wen Deng
Jun-Wen Deng
JFJian-Hong Fang
Jian-Hong Fang
We and others have shown that MPM (micropeptide in mitochondria) regulates myogenic differentiation and muscle development. However, the roles of MPM in cancer development remain unknown. Here we revealed that MPM was downregulated significantly in human hepatocellular carcinoma (HCC) tissues and its decrease was associated with increased metastasis potential and HCC recurrence. Gain- and loss-of-function investigations disclosed that in vitro migration/invasion and in vivo liver/lung metastasis of hepatoma cells were repressed by restoring MPM expression and increased by silencing MPM. Mechanism investigations revealed that MPM interacted with NDUFA7. Mitochondrial complex I activity was inhibited by overexpressing MPM and enhanced by siMPM, and this effect of siMPM was attenuated by knocking down NDUFA7. The NAD+/NADH ratio, which was regulated by complex I, was reduced by MPM but increased by siMPM. Treatment with the NAD+ precursor nicotinamide abrogated the inhibitory effect of MPM on hepatoma cell migration. Further investigations showed that miR-17-5p bound to MPM and inhibited MPM expression. miR-17-5p upregulation was associated with MPM downregulation in HCC tissues. These findings indicate that a decrease in MPM expression may promote hepatoma metastasis by increasing mitochondrial complex I activity and the NAD+/NADH ratio.

21 April 2022 in Molecular Therapy
Verified
Journal Article
Open access
YSYe Sang
Ye Sang
JLJin-Yu Liu
Jin-Yu Liu
FWFeng-Yi Wang
Feng-Yi Wang
XLXiao-Yu Luo
Xiao-Yu Luo
ZCZi-Qi Chen
Zi-Qi Chen
ZZZhu Zhu
Zhu Zhu
The roles of micropeptides in cell cycle regulation and cancer development remain largely unknown. Here we found that a micropeptide STMP1 (small transmembrane protein 1) was up-regulated in multiple malignancies including hepatocellular carcinoma (HCC), and its high level was associated with short recurrence-free survival of HCC patients. Gain- and loss-of-function analyses revealed that STMP1 accelerated cell proliferation and clonogenicity in vitro and tumor growth in vivo, and silencing STMP1 blocked G1/S transition. Mechanistically, STMP1 promoted the mRNA and protein levels of CCNE2, CDK2, and E2F1. STMP1 was localized in the inner membrane of mitochondria and interacted with mitochondrial complex IV and then enhanced its activity. Moreover, treatment with the mitochondrial complex IV inhibitor tetrathiomolybdate dramatically abrogated the promoting effect of STMP1 on cell proliferation and the expression of cyclin E2, CDK2, and E2F1. These results suggest that STMP1 may promote G1/S transition and cell proliferation by enhancing mitochondrial complex IV activity, which highlights STMP1 as a new regulator of the cell cycle and a potential target for anti-cancer therapy.

14 May 2025 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
JHJia-Hui Huang
Jia-Hui Huang
YLYi-Hang Li
Yi-Hang Li
JHJuan-Zhen Hong
Juan-Zhen Hong
RLRuo-Nan Li
Ruo-Nan Li
RWRuizhi Wang
Ruizhi Wang
ZZZhu Zhu
Zhu Zhu
Liver is the central player in maintaining metabolic homeostasis of bile acids (BAs), but how BA is tightly controlled is still largely unknown, and the role of BAs in the development of hepatocellular carcinoma (HCC) remains controversial. Here, we discovered that elevated hepatic BAs were associated with miR-122 downregulation during liver regeneration, steatosis, and fibrosis. In vivo mouse models showed that miR-122 deficiency of liver parenchymal cells (hepatocytes) in paracancerous tissues resulted in significantly increased BA levels and altered hepatic BA spectrum, thus promoting liver tumor burden, which could be abated by administration of BA sequestrant. Mechanistically, miR-122 attenuated BA production by directly targeting BA synthesis gene HSD3B7, thereby inhibiting cancer cell proliferation and HCC growth. Overexpression of HSD3B7 in hepatocytes abolished the inhibitory effect of intrahepatic delivery of miR-122 on cancer cell proliferation in c-Myc/sgTP53-induced HCC model. Consistently, lower miR-122 was associated with elevated levels of BA and HSD3B7 protein in paracancerous tissues from HCC patients and also associated with worse overall survival of HCC patients. These findings provide novel insights into the roles of miR-122-mediated BA regulatory network of liver parenchymal cells of tumor microenvironment during HCC progression, which may provide attractive therapeutic targets for HCC.

3 February 2026 in Advanced Science
Verified
Journal Article
Open access
SLSong‐Yang Li
Song‐Yang Li
JHJia‐Hui Huang
Jia‐Hui Huang
JYJin‐E Yang
Jin‐E Yang
YLYi‐Hang Li
Yi‐Hang Li
JHJuan‐Zhen Hong
Juan‐Zhen Hong
SZShi‐Mei Zhuang
Shi‐Mei Zhuang
About 25% of long noncoding RNAs (lncRNAs) contain Alu elements, yet their functional significance remains largely unexplored. We previously found that lnc‐APUE was upregulated in hepatocellular carcinoma (HCC) and correlated with high recurrence rates. However, the pathogenic roles of lnc‐APUE upregulation in tumor metastasis and its underlying mechanism are still unknown. Here, we showed that an Alu element in lnc‐APUE could base‐pair with the Alu element in 3’‐untranslated region of E‐cadherin coding gene (CDH1), triggering CDH1 mRNA decay and E‐cadherin loss, consequently enhancing hepatoma cell migration and invasion. These effects of lnc‐APUE were abrogated by deleting or mutating its Alu element, or by silencing STAU1 or UPF1, two key components of the STAU1‐mediated mRNA decay (SMD) pathway. Mouse xenograft models revealed that overexpression of wild‐type lnc‐APUE, but not Alu ‐deleted lnc‐APUE, reduced E‐cadherin levels and promoted tumor metastasis, whereas silencing lnc‐APUE had opposite effects. Furthermore, TGFβ1 stimulation induced SMAD2 binding to the lnc‐APUE promoter, activating its transcription. Silencing lnc‐APUE blocked TGFβ1‐driven migration and invasion, identifying lnc‐APUE as a downstream target and critical mediator of TGFβ1 signaling. Collectively, we define a new TGFβ1/SMAD/lnc‐APUE/E‐cadherin axis: TGFβ1 activates lnc‐APUE to promote cancer metastasis through Alu element‐driven STAU1‐mediated CDH1 mRNA decay and subsequent E‐cadherin downregulation.